TY - JOUR
T1 - Antibiotic treatment of tuberculosis
T2 - Old problems, new solutions
AU - Jain, Sanjay K.
AU - Lamichhane, Gyanu
AU - Nimmagadda, Sridhar
AU - Pomper, Martin G.
AU - Bishai, William R.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2008/6
Y1 - 2008/6
N2 - • Tuberculosis, particularly extensively drug resistant, or XDR-TB, is surging, and experts estimate 1.7 million deaths worldwide per year and 9.2 million new cases per year from TB, along with more than 2 billion people having latent infections. • Standard anti-TB therapy typically continues for six months and requires patients to take about one-third of a kilogram of a mixture of anti-TB drugs when administered daily. • While testing candidate TB drug regimens in mice is economical, reproducible, and popular, human clinical trials have not always matched the results from mice - a large moxifloxacin trial being a case in point. • Several biomarker technologies, including monitoring of mRNA and inflammatory response molecules as well as imaging with positron emission tomography and single-photon emission computed tomography, are under development to boost the speed and improve the reliability of testing anti-TB drug candidates.
AB - • Tuberculosis, particularly extensively drug resistant, or XDR-TB, is surging, and experts estimate 1.7 million deaths worldwide per year and 9.2 million new cases per year from TB, along with more than 2 billion people having latent infections. • Standard anti-TB therapy typically continues for six months and requires patients to take about one-third of a kilogram of a mixture of anti-TB drugs when administered daily. • While testing candidate TB drug regimens in mice is economical, reproducible, and popular, human clinical trials have not always matched the results from mice - a large moxifloxacin trial being a case in point. • Several biomarker technologies, including monitoring of mRNA and inflammatory response molecules as well as imaging with positron emission tomography and single-photon emission computed tomography, are under development to boost the speed and improve the reliability of testing anti-TB drug candidates.
UR - http://www.scopus.com/inward/record.url?scp=45349102658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45349102658&partnerID=8YFLogxK
U2 - 10.1128/microbe.3.285.1
DO - 10.1128/microbe.3.285.1
M3 - Review article
AN - SCOPUS:45349102658
SN - 1558-7452
VL - 3
SP - 285
EP - 292
JO - Microbe
JF - Microbe
IS - 6
ER -